Amgen (DE:AMG)

XETRA:AMG

AMG

Amgen

RESEARCH TOOLSreports

Amgen (AMG) Stock Forecast & Price Target

23 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AMG Analyst Ratings

Moderate Buy

12 Buy

11 Hold

1 Sell

Based on 24 analysts giving stock ratings to

Amgen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AMG Stock 12 Month Forecast

Average Price Target

€318.00

▲(8.89% Upside)

Based on 24 Wall Street analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is €318.00 with a high forecast of €373.86 and a low forecast of €255.30. The average price target represents a 8.89% change from the last price of €292.05.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"231":"€231","374":"€374","266.75":"€266.8","302.5":"€302.5","338.25":"€338.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":373.86153936,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€373.86</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":317.9986635135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€318.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":255.29896785,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€255.30</span>\n  </div></div>","useHTML":true}}],"tickPositions":[231,266.75,302.5,338.25,374],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,304.75,310.06627225846154,315.3825445169231,320.6988167753846,326.01508903384615,331.3313612923077,336.6476335507692,341.96390580923077,347.2801780676923,352.59645032615384,357.9127225846154,363.2289948430769,368.54526710153846,{"y":373.86153936,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,304.75,305.76912796257693,306.78825592515386,307.8073838877308,308.82651185030767,309.8456398128846,310.86476777546153,311.88389573803846,312.9030237006154,313.9221516631923,314.9412796257692,315.96040758834613,316.97953555092306,{"y":317.9986635135,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,304.75,300.94607445,297.1421489,293.33822335,289.5342978,285.73037225,281.9264467,278.12252115,274.3185956,270.51467005,266.7107445,262.90681895,259.10289339999997,{"y":255.29896785,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":280.12,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":246.475,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":246.444,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":232.405,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":249.771,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":243.227,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":252.448,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":252.004,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":289.392,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":278.369,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":289.889,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":329.2,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":304.75,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€373.86

Average Price Target€318.00

Lowest Price Target€255.30

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Gregory Renza

Truist Financial

€273.03→€278.17

Hold

-4.75%

Downside

Reiterated

04/08/26

Amgen price target raised to $325 from $319 at TruistAmgen price target raised to $325 from $319 at Truist

Carter Gould

Cantor Fitzgerald

€299.56

Hold

2.57%

Upside

Reiterated

04/08/26

Analysts Conflicted on These Healthcare Names: Amgen (NASDAQ: AMGN) and Healthequity (NASDAQ: HQY)

Geoff Meacham

Citi

€295.28

Hold

1.11%

Upside

Reiterated

04/07/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and Boston Scientific (NYSE: BSX)

Luca Issi

RBC Capital

€308.12→€316.68

Buy

8.43%

Upside

Reiterated

04/07/26

Amgen price target raised to $370 from $360 at RBC CapitalAmgen price target raised to $370 from $360 at RBC Capital

Yaron Werber

TD Cowen

€359.48

Buy

23.09%

Upside

Reiterated

04/06/26

Analysts Offer Insights on Healthcare Companies: Pro Medicus Limited (Other OTC: PMCUF) and Amgen (NASDAQ: AMGN)

Matt Phipps

William Blair

―

Buy

―

Reiterated

04/06/26

Analysts Are Bullish on Top Healthcare Stocks: Amgen (AMGN), Alector (ALEC)

Courtney Breen

Bernstein

―

Hold

―

Reiterated

04/03/26

Analysts' Top Healthcare Picks: Amgen (AMGN), Airsculpt Technologies (AIRS)

Mohit Bansal

Wells Fargo

€333.8

Hold

14.30%

Upside

Assigned

04/02/26

Wells Fargo Gives a Hold Rating to Amgen (AMGN)

David Amsellem

Piper Sandler

€369.75

Buy

26.60%

Upside

Reiterated

04/01/26

Piper Sandler Reaffirms Their Buy Rating on Amgen (AMGN)

Louise Chen

Scotiabank

€329.52

Buy

12.83%

Upside

Reiterated

03/24/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Amgen (NASDAQ: AMGN), Apogee Therapeutics (NASDAQ: APGE) and Gilead Sciences (NASDAQ: GILD)

Emily Field

Barclays

€299.56

Hold

2.57%

Upside

Assigned

03/12/26

Barclays Reaffirms Their Hold Rating on Amgen (AMGN)

Akash Tewari

Jefferies

€299.56

Hold

2.57%

Upside

Initiated

03/10/26

Amgen initiated with a Hold at JefferiesAmgen initiated with a Hold at Jefferies

Salim Syed

Mizuho Securities

€239.65→€252.49

Hold

-13.55%

Downside

Reiterated

02/11/26

Amgen price target raised to $295 from $280 at MizuhoAmgen price target raised to $295 from $280 at Mizuho

Unknown Analyst

Argus Research

Not Ranked

Argus Research

€342.36

Buy

17.23%

Upside

Reiterated

02/06/26

Amgen (AMGN) Receives a Buy from Argus Research

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

€261.05→€297

Hold

1.69%

Upside

Reiterated

02/05/26

Guggenheim Remains a Hold on Amgen (AMGN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Gregory Renza

Truist Financial

€273.03→€278.17

Hold

-4.75%

Downside

Reiterated

04/08/26

Amgen price target raised to $325 from $319 at TruistAmgen price target raised to $325 from $319 at Truist

Carter Gould

Cantor Fitzgerald

€299.56

Hold

2.57%

Upside

Reiterated

04/08/26

Analysts Conflicted on These Healthcare Names: Amgen (NASDAQ: AMGN) and Healthequity (NASDAQ: HQY)

Geoff Meacham

Citi

€295.28

Hold

1.11%

Upside

Reiterated

04/07/26

Analysts Offer Insights on Healthcare Companies: Amgen (NASDAQ: AMGN) and Boston Scientific (NYSE: BSX)

Luca Issi

RBC Capital

€308.12→€316.68

Buy

8.43%

Upside

Reiterated

04/07/26

Amgen price target raised to $370 from $360 at RBC CapitalAmgen price target raised to $370 from $360 at RBC Capital

Yaron Werber

TD Cowen

€359.48

Buy

23.09%

Upside

Reiterated

04/06/26

Analysts Offer Insights on Healthcare Companies: Pro Medicus Limited (Other OTC: PMCUF) and Amgen (NASDAQ: AMGN)

Matt Phipps

William Blair

―

Buy

―

Reiterated

04/06/26

Analysts Are Bullish on Top Healthcare Stocks: Amgen (AMGN), Alector (ALEC)

Courtney Breen

Bernstein

―

Hold

―

Reiterated

04/03/26

Analysts' Top Healthcare Picks: Amgen (AMGN), Airsculpt Technologies (AIRS)

Mohit Bansal

Wells Fargo

€333.8

Hold

14.30%

Upside

Assigned

04/02/26

Wells Fargo Gives a Hold Rating to Amgen (AMGN)

David Amsellem

Piper Sandler

€369.75

Buy

26.60%

Upside

Reiterated

04/01/26

Piper Sandler Reaffirms Their Buy Rating on Amgen (AMGN)

Louise Chen

Scotiabank

€329.52

Buy

12.83%

Upside

Reiterated

03/24/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Amgen (NASDAQ: AMGN), Apogee Therapeutics (NASDAQ: APGE) and Gilead Sciences (NASDAQ: GILD)

Emily Field

Barclays

€299.56

Hold

2.57%

Upside

Assigned

03/12/26

Barclays Reaffirms Their Hold Rating on Amgen (AMGN)

Akash Tewari

Jefferies

€299.56

Hold

2.57%

Upside

Initiated

03/10/26

Amgen initiated with a Hold at JefferiesAmgen initiated with a Hold at Jefferies

Salim Syed

Mizuho Securities

€239.65→€252.49

Hold

-13.55%

Downside

Reiterated

02/11/26

Amgen price target raised to $295 from $280 at MizuhoAmgen price target raised to $295 from $280 at Mizuho

Unknown Analyst

Argus Research

Not Ranked

Argus Research

€342.36

Buy

17.23%

Upside

Reiterated

02/06/26

Amgen (AMGN) Receives a Buy from Argus Research

Unknown Analyst

Guggenheim

Not Ranked

Guggenheim

€261.05→€297

Hold

1.69%

Upside

Reiterated

02/05/26

Guggenheim Remains a Hold on Amgen (AMGN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amgen

3 Months

xxx

Success Rate

11/15 ratings generated profit

Average Return

+7.04%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 73.33% of your transactions generating a profit, with an average return of +7.04% per trade.

1 Year

David AmsellemPiper Sandler

Success Rate

14/15 ratings generated profit

Average Return

+21.91%

Copying David Amsellem's trades and holding each position for 1 Year would result in 93.33% of your transactions generating a profit, with an average return of +21.91% per trade.

2 Years

xxx

Success Rate

15/15 ratings generated profit

Average Return

+28.40%

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +28.40% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AMG Analyst Recommendation Trends

Rating

Dec 25

Jan 26

Feb 26

Mar 26

Apr 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AMG has received 19 Buy Ratings, 18 Hold Ratings, and 0 Sell Ratings. AMG average Analyst price target in the past 3 months is 318.00.

Each month's total comprises the sum of three months' worth of ratings.

AMG Financial Forecast

AMG Earnings Forecast

Next quarter’s earnings estimate for AMG is €4.10 with a range of €3.58 to €5.27. The previous quarter’s EPS was €4.54. AMG beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year AMG has Performed in-line its overall industry.

AMG Sales Forecast

Next quarter’s sales forecast for AMG is €7.35B with a range of €7.14B to €7.94B. The previous quarter’s sales results were €8.48B. AMG beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year AMG has Performed in-line its overall industry.

AMG Stock Forecast FAQ

What is DE:AMG’s average 12-month price target, according to analysts?

Based on analyst ratings, Amgen’s 12-month average price target is 318.00.

What is DE:AMG’s upside potential, based on the analysts’ average price target?

Amgen has 8.89% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Amgen a Buy, Sell or Hold?

Amgen has a consensus rating of Moderate Buy, which is based on 12 buy ratings, 11 hold ratings and 1 sell ratings.

What is Amgen’s share price target?

The average share price target for Amgen is 318.00. This is based on 24 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €373.86 ,and the lowest forecast is €255.30. The average share price target represents 8.89% Increase from the current price of €292.05.

What do analysts say about Amgen?

Amgen’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 24 Wall Streets Analysts.

How can I buy shares of Amgen?

To buy shares of DE:AMG, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Amgen (AMG) Stock Forecast & Price Target

AMG Analyst Ratings

AMG Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Amgen

AMG Analyst Recommendation Trends

AMG Financial Forecast

AMG Earnings Forecast

AMG Sales Forecast

AMG Stock Forecast FAQ

Detailed List of Analyst Forecasts